Ascletis Pharma Inc. (ASCLF)
| Market Cap | 633.78M -47.4% |
| Revenue (ttm) | 139.41K -59.9% |
| Net Income | -87.09M |
| EPS | -0.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 0.7200 |
| Previous Close | 0.7300 |
| Day's Range | 0.7200 - 0.7200 |
| 52-Week Range | 0.7200 - 2.5000 |
| Beta | 0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 1, 2026 |
About Ascletis Pharma
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of prima... [Read more]
Financial Performance
In 2025, Ascletis Pharma's revenue was 2.03 million, an increase of 58.07% compared to the previous year's 1.28 million. Losses were -359.88 million, 19.6% more than in 2024.
Financial numbers in CNY Financial StatementsNews
Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026
- Poster presentations feature preclinical in vitro and in vivo data of potentially first-in-class oral small molecule GIPR agonist ASC48 and next-generation once-monthly to once-quarterly GLP-1R/GIPR...
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes
- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight redu...
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models. - ASC39 demonstrated eloralintide-like selectiv...
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations.
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd...
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- 48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment. - Steady-state elim...
Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
HONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that, the ordinary shares of the Company (the "Shares"), which trade on The Stock Exchange of Hong Kong...
Ascletis Pharma Earnings release: H1 2026
Ascletis Pharma released its H1 2026 earnings on August 31, 2026, summarizing the period's financial results.
Ascletis Pharma Quarterly report: H1 2026
Ascletis Pharma has published its H1 2026 quarterly earnings report on August 31, 2026.
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program...
Ascletis Pharma Slides: Corporate presentation
Ascletis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
-ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model. -Both ASC37 once-monthly subcutaneous (SQ)...
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
- ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC 50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC 50 =...
Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity
Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple asce...
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Session...
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
HONG KONG, May 5, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2...
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
HONG KONG, April 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's (ADA'...
Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
- 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. - Topline data fr...
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
-Fixed - dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-hea...
Ascletis Pharma Earnings release: H2 2025
Ascletis Pharma released its H2 2025 earnings on March 31, 2026, summarizing the period's financial results.
Ascletis Pharma Annual report: H2 2025
Ascletis Pharma has published its H2 2025 annual report on March 31, 2026.
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. - ASC30 S...
Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studie...
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
- Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. -ASC30 d emonstrated p lacebo- a djusted w eight l oss of up to 7.7% in a recently comp...
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing i...